$PEP Pushes Into Ready To Drink Booze Sodas

Yahoo Finance headline: Pepsi teases bigger alcohol push after Hard Mountain Dew launch
Brian Sozzi
Brian Sozzi·Anchor, Editor-at-Large
Wed, July 13, 2022 at 6:40 AM


After what appears to be an encouraging launch of alcohol-based Mountain Dew earlier this year, the brand’s owner PepsiCo (PEP) may be about to push deeper into the ready-to-drink booze space.

“I think we have a great product that they [Boston Beer] have developed,” PepsiCo CEO Ramon Laguarta told analysts on an earnings call Tuesday. “We’ve licensed the brand to Boston Beer, and we’re providing distribution in some states. Execution is very good. The product is turning very well, high share in those states. So it makes us feel positive about the potential of Hard Mountain Dew and the relationship with Boston Beer.”

Earlier this year, PepsiCo launched Hard Mountain Dew in partnership with Boston Beer (SAM). The 5% alcoholic drink is currently available in Tennessee, Florida, and Iowa.



Paxlovid certainly did post impressive late-stage clinical trial results, reducing the risk of hospitalisation by 89 per cent. This was far higher than its only rival oral antiviral, Merck’s Lagevrio, which cut the risk by about 30 per cent. The efficacy rate has proved a huge selling point: Pfizer expects $22bn of Paxlovid sales this year, compared to Merck’s forecast for $5bn to $5.5bn for Lagevrio.

But the trial had limitations. One was that it was in unvaccinated people, while the majority of recipients of the drug are now vaccinated.

It also focused on high-risk patients, such as those with underlying conditions. Pfizer did not report data on standard-risk patients until last month, when it stopped a trial because an interim analysis showed it was not effective in reducing symptoms. Paxlovid did reduce hospitalisations — but the study was not large enough for a statistically significant conclusion on that point.

Sorry, that should have been appended to the $PFE story . . .